Makary Resigns as FDA Commissioner Following Policy Disputes
Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization
By
Kathryn Wighton
May 12, 2026
Clinical Scorecard: Makary Resigns as FDA Commissioner Following Policy Disputes
At a Glance
Category Detail
Condition
Key Mechanisms
Target Population General public, healthcare providers, pharmaceutical companies, pediatric patients, pregnant women
Care Setting
Key Highlights
Marty Makary resigned after 13 months as FDA Commissioner, effective immediately. His tenure included significant policy disputes and workforce reductions, particularly during the COVID-19 pandemic.
Guideline-Based Recommendations
Diagnosis
Management
Focus on vaccine policy and dietary guidance initiatives, including stakeholder engagement.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
COVID-19 vaccine removed from CDC immunization schedule, impacting recommendations for healthy pediatric patients and pregnant women.
Clinical Best Practices
Support federal efforts to phase out harmful food additives, referencing FDA guidelines. Encourage reduced intake of highly processed foods, citing dietary recommendations.
References